Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis by unknown
Vashisht and Brahmachari Journal of Translational Medicine  (2015) 13:83 
DOI 10.1186/s12967-015-0443-yEDITORIAL Open AccessMetformin as a potential combination therapy
with existing front-line antibiotics for Tuberculosis
Rohit Vashisht1,2 and Samir K Brahmachari1,2,3*Abstract
Tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb) remains a global health concern. The
evolution of various multi-drug resistant strains through genetic mutations or drug tolerant strains through bacterial
persistence renders existing antibiotics ineffective. Hence there is need for the development of either new antibiotics
or rationalizing approved drugs that can be utilized in combination with existing antibiotics as a therapeutic strategy. A
comprehensive systems level mapping of metabolic complexity in Mtb revels a putative role of NDH-I in the formation
of bacterial persistence under the influence of front-line antibiotics. Possibilities of targeting bacterial NDH-I with
existing FDA approved drug for type-II diabetes, Metformin, along with existing front-line antibiotics is discussed and
proposed as a potential combination therapy for TB.
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concern with 5.4 million new cases reported in 2013 by
WHO. Globally, 5% of TB cases are estimated to have
Multi-Drug resistance TB (MDR-TB). The current anti-
TB therapy constitutes a combination of 4 different antibi-
otics, which is extremely lengthy (6–9 months) and non
compliance has resulted into the evolution of various
MDR and extensively drug resistant strains of Mycobacter-
ium tuberculosis (Mtb), the main etiological agent of hu-
man tuberculosis. The problem of antibiotic resistance
therefore renders current therapeutic interventions for the
treatment of TB ineffective and hence urges the discovery
or development of new and alternate strategies to counter
its impact. Bacteria can develop antibiotic resistance either
through genetic mutations [1] or by demonstrating bacter-
ial persistence [2] when challenged with antibiotics. While
the genetic bases of antibiotic resistance in Mtb are well
established and understood, the aspect of bacterial persist-
ence, which may result into drug tolerant phenotypes of
Mtb is seldom addressed.
In our previous analysis, by utilizing a comprehensive
in silico systems approach, we probed the metabolism in
Mtb to identify various metabolic mechanisms that may* Correspondence: skb@igib.res.in
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article, unless otherwise stated.potentiate the formation of persister phenotype in Mtb
when challenged with current front-line antibiotics of
TB therapy (Figure 1) [3]. Our analysis reveled direc-
tional re-routing of metabolic fluxes through NAD de
novo biosynthesis pathway (encoded by nadA ~ E op-
eron) and respiratory chain complex – I (NDH-I,
encoded by nuoA ~ N operon) in Mtb as a possible alter-
nate mechanism of ATP generation that may facilitate
the formation of a persister phenotype and hence dem-
onstrate antibiotic tolerance (Figure 1) [3].
Targeting proteins encoding for respiratory chain com-
plex NDH-I and NAD de novo biosynthesis pathway in
combination with targets of existing front-line antibi-
otics therefore becomes an intuitive strategy to counter
the impact of drug tolerance mediated through bacterial
persistence and hence can lead to the development of
new therapeutic intervention for the treatment of TB.
Towards this we speculate that the Metformin, an
inhibitor of mitochondrial complex-I, which is similar to
bacterial NDH-I complex can be a potential drug candi-
date that can be utilized with existing antibiotics for tar-
geting drug tolerant Mtb (Figure 1). Currently, Metformin
is an FDA approved drug that is widely used for the treat-
ment of patients with type-II diabetes [4]. The possibilities
of utilizing Metformin as a combination drug with existing
antibiotics for TB therapy are reasoned below:Med Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Metformin, an FDA approved drug for type-II diabetes as a potential combination therapy for Tuberculosis with existing
antibiotics. a) Antibiotic targeting mycolic acid biosynthesis; b) systems-level changes resulting into the reduction of flux carrying capacity of
glycolysis and citric acid cycle c) resulting re-routing of metabolic fluxes through de novo NAD biosynthesis pathway and electron transport
through NDH-I d) possibility of targeting NDH-I with metformin.
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oxidoreductase is classified into three main subunits
a) proton (H+) translocating subunit, H+ - NADH-Q
oxidoreductase (designated as NDH-I); b) sodium
(Na+) translocating subunit, Na+ - NADH-Q
oxidoreductase (designated as Na+ - NADH) and c)
NADH-Q oxidoreductase that lacks energy coupling
site and designated as NDH-II [5].
2) Earlier investigations suggest that bacterial NDH-I is
encoded by nuoA ~ N operon in E.coli [5], which is
also encoded by Mtb genome [6].
3) A comparative analysis based on subunit sequence,
cofactors and various inhibitors suggest that NDH-I
of bacteria is the counter part of mitochondrial
complex-I system [5].
4) Investigations also suggest that the bacterial
NDH-I can be inhibited by various inhibitors
of mitochondrial complex-I such as pericidin A,
capsaicin and rolliniestain-1 thereby suggesting
a common mechanism of NDH-I inhibition
by inhibitors of mitochondrial
complex – I [5].5) Metformin has been recently confirmed as inhibitor
of mitochondrial complex – I in cancer cells both
in vitro and in vivo. Study also suggests implications
of Metformin in reducing tumorigenesis [7].
Given the evidences that bacterial NDH-I complex is
similar to mitochondrial complex – I in both its struc-
ture and function [5,6] and mitochondrial complex – I
can be inhibited by Metformin [7], we therefore strongly
believe that Metformin can be a potential candidate to
inhibit NDH – I for Mtb. A recent study that appeared
while preparing this manuscript reports a host-mediated
response initiated by activation of AMPK when treated
with Metformin as a mechanism leading to inhibition of
Mtb growth, restriction in disease immunopathology
and enhancement in the efficacy of conventional drugs
[8]. While this study focused on the host-mediated
response for Mtb eradication, it however remains to be
tested if Metformin can directly bind to NDH-I of Mtb
in the presence of front-line antibiotics to elicit a bac-
tericidal effect on persister phenotypes of Mtb. Elucidat-
ing whether Metformin can directly bind to NDH-I or
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mode of action in prokaryotes and complement the on
going efforts of identifying novel combination therapy
for TB which might be effective for both drug suscep-
tible and drug resistant/tolerant bacteria.
Furthermore, our previous systems level analysis also
suggest a possible role of nadA ~ E operon (de novo
biosynthesis pathway for NAD (Figure 1(c)) in the for-
mation of persister phenotype in Mtb [3] mediated
through directional re-routing of metabolic fluxes
under the influence of front-line antibiotics. This
makes NAD de novo biosynthesis pathway (encoded by
nadA ~ E operon) an attractive combination target
along with targets of existing front-line antibiotics for
TB therapy. Designing new ligands or re-purposing the
existing compounds that can inhibit nadA ~ E operon
in Mtb in combination with front-line anti-TB antibiotics
therefore might result into novel therapeutic interventions
that can substantially aid in the ongoing efforts of TB
translation research.
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